Herzuma has been approved as a biosimilar, not as an interchangeable product.Kanjinti was approved for medical use in the European Union in May 2018.Trazimera was approved for medical use in the European Union in July 2018.Ogivri was approved for medical use in Canada in May 2019.Trazimera was approved for medical use in Canada in August 2019.Herzuma was approved for medical use in Canada in September 2019.Kanjinti was approved for medical use in Canada in February 2020.Zercepac was approved for medical use in the European Union in July 2020.Trastucip and Tuzucip were approved for medical use in Australia in July 2022. Related conjugates
Apart from the biosimilars noted above, trastuzumab is also a component of some antibody-drug conjugates, such as trastuzumab emtansine. Another ADC, trastuzumab deruxtecan was approved for use in the United States in December 2019. References
Further reading
Bazell, Robert. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998. 214 pages. ISBN 0-679-45702-X
Boseley, Sarah (29 March 2006). "The selling of a wonder drug". The Guardian. Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K (2009). "The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer". Curr Oncol. 16 (4): 25–35. doi:10.3747/co.v16i4.469. PMC 2722050. PMID 19672422. Dean L (2015). "Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype". In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520362. Bookshelf ID: NBK310376. External links

"Trastuzumab". Drug Information Portal.
Gastrocutaneous syndrome is a rare autosomal dominant cutaneous condition characterized by multiple lentigines. See also
Gardners syndrome
List of cutaneous conditions

References


== External links ==